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STATEMENT OF CLINICAL RELEVANCE  
Metabolomics is quite a novel approach in the field of hypertension research. We analysed 50 subjects 
with primary aldosteronism (PA), and 36 patients with essential hypertension (EH) using UHPLC 
MS. We processed two sample sets, one for biomarker identification and a second one for 
independent verification. The results demonstrated a strong discrimination between bilateral adrenal 
hyperplasia (BAH) individuals and all the other tested groups (up to 60-fold against aldosterone-
producing adenoma (APA) patients), and striking differences based on gender were noted. 
Independent verification of preliminary results in a second sample set confirmed that some 
metabolites (e.g., dAMP, diiodothyronine and 5-methoxytryptophan) deserve further investigation to 
validate their potential as biomarkers of the BAH subtype. Overall, our results highlight the relevance 
of state-of-the-art mass spectrometry-based metabolomics technologies in the field of hypertension 
research. We used these technologies to identify, for the first time, low molecular weight molecular 
markers of PA and paved the way for follow-up validation studies in larger cohorts.  
ABSTRACT  
Purpose: The current clinical investigation for primary aldosteronism (PA) diagnosis requires 
complex expensive tests from the initial suspicion to the final subtype classification, including 
invasive approaches; therefore, appropriate markers for subtype definition are greatly desirable. The 
present study performed a metabolomics analysis to further examine specific molecular signatures of 
PA urines. Experimental design: The study considered PA subtype and gender-related differences 
using two orthogonal advanced UHPLC-MS metabolomics approaches. We investigated patients with 
essential hypertension (n=36) and PA (n=50) who were referred to the outpatient hypertension clinic 
and included matched healthy subjects (n=10). 
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 Results: We identified statistically significant changes (p<0.05 ANOVA, Fc>1.5) of metabolites 
involved in central carbon, energy and nitrogen metabolism, especially purine and pyrimidine 
nucleosides and precursors, and free amino acids. PLS-DA interpretation provided strong evidence of 
a disease-specific metabolic pattern with dAMP, diiodothyronine and 5-methoxytryptophan as leading 
factors, and a sex-specific metabolic pattern associated with orotidine 5-phosphate, N-acetylalanine, 
hydroxyproline and cysteine. The results were verified using an independent sample set, which 
confirmed the identification of specific signatures. Conclusions and clinical relevance: 
Metabolomics was used to identify low molecular weight molecular markers of PA, which paves the 
way for follow-up validation studies in larger cohorts.  
INTRODUCTION 
Primary aldosteronism (PA) is characterized by inappropriately high aldosterone secretion, and it is 
the most common secondary form of arterial hypertension (5-15% of the hypertensive subjects) 
[1]
. 
Cardiovascular morbidity and mortality of PA patients is higher than age- and sex-matched patients 
with essential hypertension (EH) and equivalent blood pressure values 
[1- 3]
. 
Adrenal aldosterone-producing adenoma (APA) or bilateral adrenal hyperplasia (BAH) are common 
causes of PA 
[1]
. Current guidelines for PA require a complex diagnostic work-up of an initial 
screening test based on the measurement of aldosterone-to-renin ratio (ARR) and, in case of a positive 
screening test, diagnosis confirmation using a test that documents the autonomous hormone secretion 
(e.g., intravenous salt-loading test, fludrocortisone suppression test, or captopril challenge test). 
Finally, all patients with PA should be further classified for subtype (APA or BAH) using adrenal 
computed tomography (CT) scanning and adrenal venous sampling (AVS) 
[1]
. This approach is very 
important for a tailored therapy of monolateral adrenalectomy in cases of APA or pharmacological 
treatment in cases of BAH 
[1]
. 
One problem of this diagnostic work-up is the low accuracy of the screening test, which exhibits 
possible false positives and false negatives  
[1, 4]
. AVS is the gold standard for subtype classification, 
but it is an invasive procedure that is not practicable in settings other than specialist units, and it is 
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highly dependent on the operator’s skills [1, 5]. Therefore, the identification of an easy, non-invasive, 
practical and economical method for subtype classification is highly desirable. 
Metabolomics recently emerged as a powerful tool for investigating disease complexity because it 
provides a particular view of metabolites (as final products of cellular processes) of specific 
phenotypes and the phenotypic changes associated with environmental factors (e.g., diet, treatments, 
exercise, etc.). However, metabolites differ greatly in concentration, size and polarity, which makes 
their detection, quantification and identification technically challenging 
[6]
. Urine has gained growing 
importance in metabolomic analyses, especially clinical practice, because of its non-invasive and easy 
collection 
[7]
. Another advantage of working with urine is that the concentrations of metabolites are 
often higher than plasma. However, urinary metabolomics remains an emerging approach in the field 
of hypertension research, and a limited number of human studies are available 
[8]
. 
Our previous studies demonstrated sex-related differences in some proteins related to APA and BAH 
[9]
, and the present study performed a metabolomics analysis to further identify the specific molecular 
signatures of PA urine. The study used an advanced UHPLC-MS metabolomics workflow 
[10]
 to 
analyse the metabolic profiles of control normotensive subjects, patients with EH, and PA individuals 
(APA or BAH). The potential biomarkers identified using these untargeted platforms were further 
verified using an orthogonal semi-targeted approach, and the results pave the way for future validation 
in larger cohorts using targeted approaches in the near future. 
MATERIALS AND METHODS  
Selection of subjects 
The study was performed according to the principles of the Declaration of Helsinki. Each healthy 
individual or patient provided written informed consent. The Institutional Review Board Ethical 
Committee approved the protocol. Second morning urine samples and a blood sample for biochemical 
routine parameter analysis were collected from each subject. All analysed subjects were in fasting 
conditions at the time of sampling. Smoking habits were reported.  
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Subjects in the experimental groups analysed in this study were carefully selected to avoid 
confounding factors, and all of the procedures for sample handling and storage were highly 
standardized.  
1) Normotensive healthy subjects 
Ten normotensive healthy volunteers, five women and five men, were selected for the metabolomic 
study from healthy volunteers participating in a phase 2 trial study at the Centre for Clinical Research 
of the Azienda Ospedaliera-Universitaria of Verona, Italy. The following inclusion criteria were used: 
no history of past, recent or concomitant significant illness; regular menstrual cycles; no drug intake 
within 4 weeks prior to the examination; no personal or family history of hypertension; and at least 
two confirmed normal blood pressure (BP) values during the first visit. 
2) Hypertensive subjects 
Patients were recruited from two different hypertension units (Verona and Turin, Italy). Protocols for 
sample collection, preparation and storage were the same for both centres.  
Patients took no antihypertensive drugs, other than verapamil and/or alpha-blockers, in the previous 4 
weeks. Hypokalemia was corrected when present. Hypertensive women receiving oral contraceptive 
therapy were excluded.  
The criteria for PA diagnosis were described previously [9, 11]. Briefly, orthostatic ARR higher than the 
reference value established for each laboratory (32 pg/ml for ratio of aldosterone, expressed as pg/ml, 
to direct active renin, expressed as pg/ml [12]; 40 for ratio of aldosterone expressed as ng/dl to renin 
activity expressed as ng/ml•h in Turin [11]) and positive iv SLT. The test was considered positive when 
PAC levels were higher than 50 pg/ml at the end of the test [11]. 
The classification for subtypes for PA diagnoses (i.e., BAH or APA) was based on adrenal CT and 
AVS [13]. Other hypertensive subjects, diagnosed as EH, were included in the study, and exhibited 
orthostatic ARR lower than the reference value for PA screening (low ARR) or an ARR higher than 
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the reference value but a negative iv SLT (high ARR). These subjects represent a group of patients 
with hypertension without PA. 
We first analysed a sample group composed of 10 BAH and 10 APA subjects, in equal numbers of 
males and females, and 12 EH subjects (six high ARR and six low ARR) for the metabolomics study. 
We added an additional group of patients to the study as a verification set, which was composed of PA 
(n=19; F=8, M=11) and EH (n=7, F= 3, M=4) subjects. We also analysed another group of samples at 
the Metabolomics Facility of the University of Colorado, Denver using a different high-resolution MS 
platform for an independent validation of the results. 
This new group of samples was subdivided into a training set and test set, and it was composed of the 
previous cohort and newly enrolled subjects. The training set included, 10 normotensive subjects, 12 
APA (F=6, M=6), 12 BAH (F=5, M=7), 10 low ARR (F=5, M=5) and 9 high ARR (F=4, M=5) 
subjects. The test set was composed of 20 PA patients (APA=13, BAH=7), including PA of 
undetermined subtype (n=6) and EH subjects (n=17). 
 Biochemical assay 
The Laboratory of the Verona and Turin University Clinical Chemistry Institutes performed 




Minimally processed urine samples were used for the metabolomics analysis. People who materially 
performed the assays were unaware of the previous clinical diagnosis of each patient. Samples were 
stored at -80°C until thawing. Samples were centrifuged at 13500 g at 4°C for 15 minutes to discard 
the debris. A volume of 0.5 ml of the centrifuged urines was added to 0.5 ml of a -20°C cold 
methanol/acetonitrile/bidistilled water solution (5/3/2 vol/vol/vol) and subjected to a further 
centrifugation using the previous conditions. The supernatants were used for the analysis. Samples 
were loaded onto a rapid resolution HPLC system (LC Packings, DIONEX, CA, USA) for 
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chromatographic separation of hydrophilic metabolites. The system featured a binary pump and 
vacuum degasser, well-plate autosampler with a six-port micro-switching valve and a thermostated 
column compartment. A Phenomenex Luna 3-µm HILIC 200A (150x2.0 mm) column, protected by a 
guard column HILIC 4x2.0 mm ID (Phenomenex, CA, USA) was used to perform metabolite 
separation over a phase B (100% acetonitrile, 10 mM ammonium acetate) to phase A (double distilled 
18 mΩ water, 10 mM ammonium acetate) gradient for 35 minutes. Urinary creatinine was obtained 
for each sample, and samples of less concentrated urine were normalized using a simple 
preacquisition strategy based on differential injection volumes calibrated by creatinine. This 
normalization method is more effective compared to other methods 
[14]
. We set the following LC 
parameters: column temperature of 25°C and flow rate of 0.3 ml/min. The following multistep 
gradient was set: 0-5 minutes 100% phase B; 5-15 minutes from 100% phase B to 70% phase B; 15-
20 minutes from 70% phase B to 50% phase B; 20-25 minutes from 50% phase B to 0% phase B; 25-
30 minutes isocratic at 0% phase B; 30-30.1 minutes return to the initial conditions 100% phase B; 
and 30.1-35 minutes isocratic column equilibration at 100% phase B. 
The eluate from the HPLC system was linked online with a Micro Q-TOF II (Bruker Daltonics, 
Bremen, Germany) mass spectrometer equipped with an ESI ion source. Instrument calibration was 
performed externally using a sodium formate solution consisting of 10 mM sodium hydroxide in 50% 
isopropanol/water (v/v) and 0.1% formic acid. External mass scale calibration was performed twice 
daily via direct automated injection of the calibration solution from a 6-port divert-valve. Mass 
spectrometer runs were exported into mzXML files and analysed using the software MAVEN
[15]
 for 
correct metabolite assignment, on the basis of absolute intact mass (within a 10 ppm window) against 
the KEGG database,
[16]
 and expected retention times on the basis of metabolite chemical properties 
and in-house available standards (SIGMA Aldrich, St. Louis, MO). We used an automatic research 
method for each couple of compared groups and allowed the software MAVEN to construct a list of 
the metabolites that exhibited differential relative abundance (setting the fold-change cut-off >1.5) 
and statistical significance (p<0.05; FDR < 0.1). Heat maps were generated using the software GENE 
E (Broad Institute, MA, USA). 
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Independent, orthogonal validation analyses were performed at the University of Colorado Denver – 
Anschutz Medical Campus. Briefly, the analytical platform used a Vanquish UHPLC system (Thermo 
Fisher Scientific, San Jose, CA, USA) coupled online to a Q Exactive mass spectrometer (Thermo 
Fisher Scientific, San Jose, CA, USA). Samples were resolved over an ACQUITY HSS T3 column 
(2.1 x 150 mm, 1.8 µm particle size (Waters, MA, USA) using a gradient from 0- 5% B over 0.5 
minutes, 5-95% B over 0.6 minutes, held at 95% B for 1.65 minutes, 95-5% B over 0.25 minutes, held 
at 5% B for 2 minutes, and flowing at 450 µl/min at 35ºC. The Q Exactive mass spectrometer 
(Thermo Fisher Scientific, San Jose, CA, USA) was operated independently in positive or negative 
ion mode, and scanning was performed in Full MS mode (2 μscans) from 150 to 1500 m/z at 70,000 
resolution, with 4-kV spray voltage, 45 shealth gas, and 15 auxiliary gas. Automatic dd-MS2 was 
performed at 17,500 resolution, AGC target = 1e5, maximum IT = 50 ms, and stepped NCE of 25 or 
35 for positive mode, and 20, 24, and 28 for negative mode. Calibration was performed prior to 
analysis using the PierceTM Positive and Negative Ion Calibration Solutions (Thermo Fisher 
Scientific). Acquired data were converted from.raw to.mzXML file format using Mass Matrix 
(Cleveland, OH, USA). Samples were analysed in a randomized order with a technical mixture 
injected incrementally to qualify instrument performance. This technical mixture was also injected 
three times per polarity mode and analysed using the parameters described above, except CID 
fragmentation was included for unknown compound identification. Metabolite assignments, 
isotopologue distributions, and corrections for expected natural abundances of deuterium, 13C, and 
15N isotopes were performed using MAVEN (Princeton, NJ, USA), against an in-house library of 
~1,000 standards. Discovery mode analysis was performed with standard workflows using Compound 
Discoverer (Thermo Fisher Scientific, San Jose, CA).  
Statistical analysis 
The LC/MS data were exported into Microsoft Excel. The resulting data were processed using partial 
least squares discriminant analysis (PLS-DA) in Multibase software (Numerical Dynamics) and 
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. PLS-DA was used to identify differences between the experimental groups. 
The loading plots, where each metabolite (loading variable) is evidenced by a point, were used to 
identify the metabolites that were responsible for the separation of the samples on the score plots via 
sorting metabolites on the basis of loading weights on PC1, PC2 and PC3. 
Statistical analysis was performed using SPSS for Windows software (Version 21.0; SPSS, IBM). 
Independent samples t-test or ANOVA were used to analyse differences between metabolites groups, 
and a p-value < 0.05 was considered statistically significant. The use of a statistical method was 
necessary in the search for a key to interpret the large quantity of data from the metabolomic 
untargeted analysis. Our research involved five different groups of subjects, and the number of 
possible combinations for couple-comparative studies was rather large. We chose PLS-DA because it 
relates the data matrix (e.g., multivariate metabolite data) to the response vector (containing the 
sample class affiliations, e.g., case-control) using a linear regression model. Principal component 
analysis (PCA), on which PLS-DA is based, reduces the multidimensionality of data sets with a large 
number of variables (variable=metabolite) in a lower-dimensional space, where the first principal 
components explain as much of the existing covariance as possible. 
Random forest clustering, heat maps, and determinations of VIP scores were calculated and plotted 
using the software Metaboanalyst 3.0 
[17]
. 
Comparisons between the clinical and biochemical characteristics of patients’ groups were performed 
using 2-tailed unpaired Student’s t test. Values are expressed as the means ± standard deviation, and 
logarithmic transformation was performed on skewed variables to normalize their distribution, which 
are presented as geometric means (antilogarithms of the transformed means) with estimations of 95% 
confidence intervals (CIs). Comparisons of proportions were performed using cross-tabulation, 
Pearson’s chi-square and Fisher’s exact tests. 
RESULTS 
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Our strategy and experimental workflow involved the use of second morning urine, minimal sample 
processing to preserve the “original” metabolites, chromatographic separation coupled with mass 
spectrometry and statistical analysis. The hypertensive population (PA and EH) was further 
subdivided into BAH and APA for the PA group, and high ARR or low ARR, for the EH group.  
Supplemental Tables 1 and 2 report the clinical and biochemical characteristics of the entire 
population of PA and EH patients and APA and BAH. No significant differences were observed 
between groups, with the exception of higher aldosterone and lower K
+
 values in PA versus EH 
patients, as expected. 
The metabolomics analysis created a list of metabolites that were differentially represented between 
groups (See Supplemental Table 3 for the list of all metabolites). We identified a panel of highly 
statistically significant (p<0.05 ANOVA, Fc>1.5 up to 60-fold) changes of metabolites involved in 
central carbon, energy and nitrogen metabolism. We also performed comparisons based on gender and 
the specific hypertensive subgroup classification (normal female, normal male, APA female, APA 
male, BAH female, BAH male, high ARR female, high ARR male, low ARR female, and low ARR 
male). PLS-DA was performed to determine whether metabolic phenotypes could be used to 
discriminate between sub-groups (Figure 1A). Notably, principal component 1 (PC1, explaining 
>10% of the total variance) discriminated BAH samples from all other groups. PC2 exhibited a 
signature associated with gender (female vs. male) and hypertension (in the presence or absence of 
APA and BAH, EH with low ARR and high ARR, of PA traits –Figure 1A). PLS-DA clustering was 
validated using random permutation, random forest clustering and hierarchical clustering (Figure 1A-
E), and all of the algorithms confirmed a distinct signature associated with PA subjects, especially in 
the female groups. Variables (metabolites) were sorted by fold-change and p values (ANOVA) across 
groups to determine significant features (Significant Analysis of Microarrays (SAM) plot; Figure 1C) 
and VIP scores (Figure 1D). The results indicated that pyrimidine nucleoside and precursors (dUMP, 
orotidine phosphate, thiamine phosphate, UMP, UDP, uracil), purine nucleotides and catabolites 
(adenosine, uric acid) and free amino acids (histidine, cysteine, N-acetyl-lysine, N-acetyl-glutamine) 
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were the metabolites with the highest discriminating power among the classes of samples (Figure 1D). 
Heat map representation of the top metabolic signatures in normal, EH and PA urines revealed further 
components of this response, such as acetyl-alanine, taurine and hydroxyproline, which is a marker of 
extracellular matrix remodelling and collagen turn-over 
[18]
 (Figure 1E). Box and whisker plots for 
metabolites exhibiting the highest discrimination power (ANOVA) across samples are presented in 
Figure 2. The subgroups of EH subjects (low ARR and high ARR) always mapped together in the 
same quadrant in the PLS-DA analyses (Figure 1A), which indicates that no metabolic markers that 
could significantly discriminate between these subgroups were identified, at least in this preliminary 
metabolomic characterization.  
The comparison of total normal subjects (males and females) with the PA subjects demonstrated that 
glycolytic intermediates 2/3-phosphoglycerate and dihydroxyacetone phosphate and pyrimidine UMP, 
both in the ribose and deoxyribose (dUMP) sugar nucleoside form, exhibited the highest 
discriminatory potential between normal and PA urines (Figure 3A). 
A subset of markers reliably discriminated between urines from EH and PA patients (Figure 3B), as 
extensively detailed in Table 1. Markers included purine nucleosides and related catabolites, 
deoxyadenosine and uric acid (Figure 3B). Similarly, the adenosine deamination catabolites 
deoxyinosine, hypoxanthine and IMP, and free amino acids histidine and taurine and the pyrimidine 
diphosphate CDP exhibited high discriminatory power when comparing APA vs. BAH groups in a 
gender-independent manner (Figure 3C). The p values of these latter metabolites are also available in 
Supplementary Table 5. Independent verification of these observations was pursued at the University 
of Colorado Denver on the same samples and identified similar metabolic specificities across urine 
samples for sulfurs (methionine, methionine sulfoxide, sulfinoalanine), purines (adenosine, guanosine, 
guanine, xanthine, hydroxyisourate), and pyrimidines (dihydrouracil, uracil), which confirmed the 
observations from our preliminary analyses (Supplementary Figure 1– Training cohort).  
Therefore, we performed a validation study based on a second sample set using targeted relative 
quantitation of metabolites with the highest loading weights in the PLS-DA analysis (Figure 1D). The 
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results confirmed the discriminatory capacity of several metabolites (as gleaned by PLS-DA 
elaboration, Figure 4A), including but not limited to dAMP (BAH males vs. normal males), cysteine 
(BAH females vs. APA females), diiodothyronine (BAH males vs. APA males) (Figure 4B and 
Supplemental Table 4). Elaboration of this verification sample set led to the identification of some 
metabolites, such as dAMP, methoxytryptophan and diiodothyronine, as discriminating-disease 
metabolites, and the comparison of normal and BAH males revealed strong differences in the relative 
abundance of dAMP in the two considered groups, as expected (Figure 4B). Similar trends were 
observed following the relative quantitation of methoxytryptophan and diiodothyronine in BAH/APA 
males (Figure 4B). Each discriminating metabolite exhibited similar behaviour in all possible pair-
comparisons between clustered groups. Relative P values are also available for these metabolites in 
Supplementary Table 6A and 6B. 
A secondary untargeted metabolomics analysis confirmed and expanded the data from the first 
analytical site. We detected a dysregulation of urine levels of sulfur-containing metabolites 
(thiocysteine, homomethionine), purines (S-adenosylhomocysteine, AMP, allantoate, 
hydroxyisourate), pyrimidines (dihydrothymine, uracil, UDP), arginine metabolism (arginine, 
creatinine, guanidine oxopentanoate), tryptophan metabolism (hydroxykynurenic acid) and sugars 
(rhamnose, mannitol) in both cohorts, especially in the EH and BAH groups (Supplementary Figure 
1 and 2 – Training and testing cohort). 
DISCUSSION 
Our exploratory investigation highlights, for the first time, the presence of gender and PA subtype-
specific alterations in the urinary metabolome. Other investigators previously observed that the 
careful selection of patients was of crucial importance, especially in multifactorial diseases, such as 
hypertension
[8]
. Our results are consistent with previous reports of an altered energy metabolism 
associated with hypertension 
[8]
. The observed gender-related differences are also consistent with our 
previous study on urinary proteomics in primary aldosteronism 
[9]
 and hormone-dependent changes in 
females 
[19]
, which confirms a gender-specific signature reflected in a diversified urinary metabolome, 
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as described in the present results. Our findings on an involvement of purine/pyrimidine pathways 
suggest a disturbance of this metabolism in hypertensive patients, which is a phenomenon previously 
described by others in other settings 
[20]
. This observation is also consistent with previous data 
collected from patients who were characterized by increased plasma renin activity in the absence of 
increased plasma levels of aldosterone following treatment with minoxidil 
[21]
. Increased free levels of 
amino acids, especially N-acetylated forms, suggest augmented proteolysis of N-terminal-acetylated 
residues 
[22,23]
. The presence of metabolites, such as amino acids, was also previously reported to 
characterize women who develop preeclampsia 
[24]
. Metabolites related to altered lipid and 
carbohydrate metabolism are generally associated with hypertension 
[8]
. A very recent report by Zhao 
and colleagues revealed the involvement of amino acid metabolism and oxidative stress metabolic 
pathways in a study of urine metabolomics during the course of essential hypertension 
[25]
. 
Gender-specific abnormality previously emerged as a relevant question relevant in the pathogenesis 
and diagnostic work-up of PA. The recent discovery of somatic mutations on several genes coding for 
K channels or other molecules involved in cell ion homeostasis clarified the pathogenesis of APA. A 
recent meta-analysis demonstrated that female gender is largely prevalent (67% vs. 44%, p<0.05) in 
patients with APA and KCNJ5 mutation, which is the most frequent genetic abnormality recognized 
in adrenal glands with adenomatous transformation 
[26]
. The findings of the largest studies on this 
topic confirmed this result 
[27-30]
. A very recent report further confirmed the female prevalence of the 
KCNJ5 mutation in APA 
[31]
. Williams and colleagues recently discussed a gender-related prevalence 
in APA patients and other aspects, such as dietary salt intake and cultural behaviours in different parts 
of the world 
[32]
. 
Possible influences on steroid adrenal production by female sex hormones were hypothesized, but the 
precise mechanisms underlying this association remains largely unknown and worthy of further 
specific research.  
Gender also affects the diagnostic work-up for PA. We first demonstrated that the initial screening 
based on the determination of ARR must be differentiated by gender because fertile women may 
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exhibit sex hormone-dependent changes of ARR, which leads to false positive results more frequently 
than in males
[33]
 . Other investigators subsequently confirmed these findings 
[1,4]
. 
Therefore, numerous pieces of evidence clearly support gender-specific features in PA patients who 
must be considered in clinics. The present data on the urinary metabolomics strongly support this 
view and suggest further investigations to identify new, clinically useful biomarkers.  
The application of metabolomics technology in the current exploratory study elucidated peculiar 
metabolic signatures in the urine of patients diagnosed with different subtypes of PA. The results 
demonstrated a strong discrimination of BAH individuals from all other groups (up to 60-fold 
difference from APA patients), and a striking difference based on gender. These results indicate that 
the urinary metabolome of BAH patients is clearly different from other PA patients and presents 
gender-specific signatures. Notably, independent verification of preliminary results in a second 
sample set confirmed that three metabolites, dAMP, diiodothyronine and 5-methoxytryptophan, 
deserve further investigation to validate their potential as biomarkers of the BAH subtype. However, 
gender discrimination in the BAH subtype was based on determination of the levels of orotidine 5-
phosphate, N-acetylalanine, hydroxyproline and cysteine.  
Our study presents elements of strengths and limitations. The characterization by AVS of the “true” 
diagnosis of PA subtype is surely important because the strict criteria of lateralization allows for clear 
results and sure definitions of the pathology. The discrimination of the PA subtype was also very 
recently obtained using LC/MSMS steroid profiling in peripheral and AVS plasma samples, which 
provided better performance in detecting lateralization than that of aldosterone immunoassay 
[34,35]
. A 
second important strength was the use of high-resolution UPLC:MS/MS approaches to obtain further 
independent validation of the data.    
The main limitation of the present study is the relatively limited patient sample size used for the 
analysis. Therefore, we used a double control of the data with i) a first exploratory sample of subjects, 
followed by an analysis of validation on a second sample, and ii) a second independent validation 
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analysis performed at the University of Colorado using another analytical platform. The internal 
substantial consistency of the results supports their reliability and the use of some metabolites as 
discriminating factors for the diagnosis of PA or PA subtype. Further and larger studies based on the 
absolute measurements of selected metabolites are required for clinical application. The possibility to 
initially separate BAH from APAs would avoid AVS, which is an invasive and difficult procedure 
that is currently available only in experienced and specialized centres and that fully relies on the 
technical skills of the operator. Notably, the subtype definition is critical for successful patient 
treatment and BP normalization.  
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Table 1. Metabolic contributors to PLS-DA clustering patterns in PA vs. EH. T-test p-values are 
reported; not all PLS-DA metabolites contributors reached statistical significance.  
Metabolite Pathway and physiological role p-Value Fold change 
dAMP Purine pathway ns 2.18 up, PA 
Methoxytryptophan Trp derivative. Antihypertensive activity 
[36]
  ns 2.47 up, PA 
Diiodothyronine 
Metabolically active iodothyronine; involved in 
energy metabolism and cellular respiration 
[37]
. 
ns 4.43 up, PA 
Orotidine 5 
phosphate 
Precursor of UMP 
0.016 19.2 up, PA 
Hydroxyproline Associated with a high risk of heart failure 
[38]
 . 0.05 4.12 up, PA  
N acetylalanine 
Fundamental in collagen structure. Its high 
myocardial concentration is related to fibrosis 
and heart failure 
[39]
. 
ns 1.60 up, PA  
Cysteine 
High levels in plasma are related to high risk of 
coronary heart disease 
[40]
  
0.02 3.02 up, PA 
Xanthosine 5 
phosphate 
Intermediate in purine metabolism. 
0.037 4.39 up, PA 
Argininosuccinate 
Precursor of fumarate in Krebs cycle; precursor 
of arginine in urea cycle. 
0.026 3.23 up, PA 
Uric acid  purine pathway, byproduct of purine breakdown 0.02 2.85 up, PA 
deoxyadenosine purine pathway, catabolite of adenosine. 0.1 3.93 up, PA 
CMP 
Pyrimidine metabolism. The main source is 
RNA degraded by RNAses, which frees UTP, 
which is deaminated to CTP. 
0.0431 1.75 up, PA 
Dihyroxyacetone 
phosphate 
Intermediate in glycolysis, gluconeogenesis and 
triglycerides synthesis. 
ns 1.99 up, PA 
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Phosphoglycerate Intermediate of glycolysis. 0.05 1.82 up, EH 
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Figure 1. Statistical analyses. (A) PLS-DA was performed to determine whether metabolic 
phenotypes could discriminate urine samples from male or female subjects who were healthy, 
hypertensive without primary aldosteronism (PA) and a low/high aldosterone-to-renin ratio (ARR), or 
with P, divided into bilateral hyperplasia patients (BAH) and adrenal adenoma-producing aldosterone 
patients (APA). Principal component 1 (PC1) explained ~13% of the total variance and discriminated 
BAH samples from other groups. PC2 discriminated female (upper) from male (lower quadrant) 
samples and provided discrimination between normal urine (top quadrant) and hypertensive samples 
(lower quadrants). (B) Random forest clustering confirmed PLS-DA profiles, and BAH samples 
exhibited distinct phenotypes compared to other groups. (C) SAM plot identified at least 16 
significant features exhibiting discriminating capacity between groups. (D) Significant metabolites 
with discriminatory capacity between groups were plotted using VIP scores. (E) The same 
metabolites, and additional metabolites primarily related to purine/pyrimidine metabolism and free/N-
acetylated amino acids, were statistically significant (p<0.05 ANOVA) using hierarchical clustering 
analysis. 
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Figure 2. Box and whisker plots of metabolites with significant discriminatory capacity between 
groups. Medians + interquartile ranges are shown for each metabolite. 
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Figure 3. Whisker plots of the metabolites exhibiting discrimination between normal and PA 
samples (BAH and APA). (A), essential hypertensive (EH) and PA samples (B), and PA subtypes, 
defined as bilateral hyperplasia patients (BAH) and adrenal adenoma-producing aldosterone patients 
(APA) (C). Medians + interquartile ranges are shown for each metabolite. 
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Figure 4. Verification of the results was performed via monitoring of the top discriminating 
metabolites from the first analysis in an independent sample set. (A) A PLS-DA analysis was 
performed on 11 metabolites of 26 EH or PA (BAH and APA) samples, female or male (detailed in 
Supplemental Table 2). Verification results confirm the discriminatory capacity of the biomarkers 
identified in the first analysis, but further, more extensive prospective validation using targeted 
approaches in a novel cohort is mandatory. (B) Box and whisker plots for 10 representative 
metabolites, as predicted in the first dataset and verified using targeted approaches in a second 
independent dataset. Medians + interquartile ranges are shown for each metabolite. Colour codes are 
consistent with the box and whisker plots in Figure 2. 
 
 
